Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
clinical trial
|
| gptkbp:analyzes |
conducted by independent statisticians
|
| gptkbp:built |
2018-12-31
|
| gptkbp:class |
immune checkpoint inhibitor
|
| gptkbp:clinicalTrials |
therapeutic efficacy assessment
NCT02302807 demonstrated efficacy in treatment |
| gptkbp:collaborations |
various academic institutions
|
| gptkbp:collection |
prospective
|
| gptkbp:complications |
monitored throughout the trial
|
| gptkbp:country |
gptkb:Canada
gptkb:United_States Europe |
| gptkbp:criteria |
adult patients
active autoimmune disease |
| gptkbp:dataTransmission |
available upon request
|
| gptkbp:diseaseResistance |
urothelial carcinoma
|
| gptkbp:drugInterdiction |
gptkb:Atezolizumab
|
| gptkbp:enrollment |
gptkb:metastatic_urothelial_carcinoma
diverse population approximately 300 patients |
| gptkbp:finaleDate |
2018-12-31
|
| gptkbp:funding |
provided_by_Roche
|
| gptkbp:future_plans |
Phase II
guides treatment protocols. |
| gptkbp:healthcare |
obtained prior to participation
|
| gptkbp:historical_analysis |
included in the study
|
| https://www.w3.org/2000/01/rdf-schema#label |
IMvigor211
|
| gptkbp:impact |
gptkb:Atezolizumab
up to 2 years |
| gptkbp:is_studied_in |
achieved primary goals
non-randomized |
| gptkbp:launchDate |
2015-09-01
|
| gptkbp:location |
multiple sites
|
| gptkbp:model |
single group assignment
|
| gptkbp:notableWork |
influenced future studies
|
| gptkbp:outcome |
The Lancet Oncology
overall survival progression-free survival |
| gptkbp:period |
up to 2 years
|
| gptkbp:primaryMission |
overall response rate
|
| gptkbp:publishes |
2019
|
| gptkbp:regulatoryCompliance |
FDA_approved
EMA_approved |
| gptkbp:releaseYear |
2019
|
| gptkbp:research |
contributed to oncology knowledge base
|
| gptkbp:responseTime |
RECIST criteria
|
| gptkbp:result |
published in peer-reviewed journals
improved overall survival in certain populations |
| gptkbp:safety_features |
assessed during the trial
|
| gptkbp:secondary_mission |
gptkb:Dr._Thomas_Powles
|
| gptkbp:secondaryMission |
duration of response
|
| gptkbp:sponsor |
gptkb:Roche
|
| gptkbp:status |
completed
|
| gptkbp:targets |
gptkb:PD-L1
|
| gptkbp:visibility |
open label
|